Syncom Formulations Gains 8.18%: 3 Key Factors Driving the Move
2026-11-21 15:03:23Key Events This Week 16 Nov: Stock opens at ₹21.10, up 3.94% on strong volume 19 Nov: Mojo Grade upgraded to Buy; shares jump 5.55% to ₹22.06 20 Nov: Valuation grade shifts to very expensive amid sector dynamics 20 Nov: Week closes at ₹21.96, up 8.18% for the week Week OpenRs.20.30 Week CloseRs...
Read More
Syncom Formulations: Valuation Shift Signals Heightened Price Attractiveness Amidst Sector Dynamics
2026-11-20 08:00:33Syncom Formulations (India) Ltd has recently undergone a significant change in its valuation parameters, shifting from an expensive to a very expensive rating. This adjustment reflects evolving market perceptions and invites investors to reassess the stock’s price attractiveness in the context of its financial metrics, peer comparisons, and historical performance.
Read More
Syncom Formulations Shares Gain Momentum as Technical Indicators Turn Bullish
2026-11-19 08:04:07Syncom Formulations (India) Ltd has demonstrated a notable shift in price momentum, moving from a mildly bullish to a bullish technical trend, supported by a confluence of positive signals across key indicators such as MACD, RSI, moving averages, and Bollinger Bands. This micro-cap pharmaceutical stock’s recent performance and technical upgrades suggest growing investor confidence amid a challenging sector backdrop.
Read More
Syncom Formulations (India) Ltd is Rated Hold
2026-11-14 10:10:04Syncom Formulations (India) Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 24 August 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 14 November 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Read More
Syncom Formulations (India) Ltd Shows Bullish Momentum Amid Technical Upgrades
2026-11-05 08:04:40Syncom Formulations (India) Ltd has demonstrated a notable shift in price momentum, supported by a series of bullish technical indicators. The micro-cap pharmaceutical company’s recent upgrade from a Sell to a Hold rating reflects improving market sentiment and technical strength, signalling potential opportunities for investors amid a volatile sector backdrop.
Read MoreSyncom Formulations Falls 9.24%: 3 Key Factors Driving the Weekly Decline
2026-10-31 15:03:20Key Events This Week Oct 26: Valuation shift signals renewed investor interest Oct 28: Technical indicators turn bullish amid price rebound Oct 29: Technical momentum shifts to mildly bullish with consolidation Oct 30: Week closes lower at Rs.19.25 (-5.54% on day) Week OpenRs.21.21 Week CloseRs...
Read More
Syncom Formulations (India) Ltd: Technical Momentum Shifts Signal Mildly Bullish Outlook
2026-10-29 08:02:16Syncom Formulations (India) Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a bullish to a mildly bullish stance. Despite a recent dip in daily price, key technical indicators such as MACD and KST maintain bullish signals on weekly and monthly charts, while moving averages and Bollinger Bands suggest cautious optimism. This nuanced technical landscape offers investors a complex picture amid broader market volatility.
Read More
Syncom Formulations Shares Gain Momentum as Technical Indicators Turn Bullish
2026-10-28 08:04:10Syncom Formulations (India) Ltd has experienced a notable shift in its technical momentum, moving from a mildly bullish stance to a more confident bullish trend. This change is underpinned by improvements across key technical indicators including MACD, moving averages, and Bollinger Bands, signalling renewed investor interest in this pharmaceuticals and biotechnology micro-cap stock.
Read More
Syncom Formulations Valuation Shift Signals Renewed Investor Interest
2026-10-26 08:01:29Syncom Formulations (India) Ltd has witnessed a notable shift in its valuation parameters, moving from a very expensive to an expensive rating, reflecting a recalibration of price attractiveness amid robust financial performance and sector dynamics. This change, coupled with a recent upgrade in its Mojo Grade from Sell to Hold, underscores evolving investor sentiment in the Pharmaceuticals & Biotechnology micro-cap space.
Read MoreAnnouncement under Regulation 30 (LODR)-Newspaper Publication
14-Nov-2026 | Source : BSESubmission of Press Clipping regarding publication of extract of Unaudited Standalone and Consolidated Financial Results for the Quarter/Half Year ended on 30th September 2026
Submission Of Standalone & Consolidated Unaudited Financial Results For The Quarter And Half Year Ended On 30Th September 2026 Pursuant To Regulation 33(3) Of The SEBI (LODR) Regulations 2015
13-Nov-2026 | Source : BSESubmission of standalone & Consolidated Unaudited Financial Results along with limited review report statement of assets and liabilities and cash flow statements for the Quarter and Half year ended on 30th September 2026 pursuant to regulation 33(3) of the SEBI (LODR) Regulations 2015
Board Meeting Outcome for Submission Of Standalone & Consolidated Unaudited Financial Results For The Quarter And Half Year Ended On 30Th September 2026 Pursuant To Regulation 33(3) Of The SEBI (LODR) Regulations 2015.
13-Nov-2026 | Source : BSEPursuant to Regulation 33(3) of SEBI (LODR) Regulations 2015 we are pleased to submit herewith the following:
Corporate Actions
No Upcoming Board Meetings
Syncom Formulations (India) Ltd has declared 10% dividend, ex-date: 23 Sep 26
Syncom Formulations (India) Ltd has announced 1:10 stock split, ex-date: 19 Aug 13
Syncom Formulations (India) Ltd has announced 5:2 bonus issue, ex-date: 19 Aug 13
Syncom Formulations (India) Ltd has announced 1:2 rights issue, ex-date: 13 May 09